NO990088D0 - Farmas÷ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindamin - Google Patents
Farmas÷ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindaminInfo
- Publication number
- NO990088D0 NO990088D0 NO990088A NO990088A NO990088D0 NO 990088 D0 NO990088 D0 NO 990088D0 NO 990088 A NO990088 A NO 990088A NO 990088 A NO990088 A NO 990088A NO 990088 D0 NO990088 D0 NO 990088D0
- Authority
- NO
- Norway
- Prior art keywords
- disease
- aminoindamine
- propargyl
- pharmaceutical compositions
- injury
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11883696A IL118836A (en) | 1996-07-11 | 1996-07-11 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
PCT/IL1997/000205 WO1998002152A1 (en) | 1996-07-11 | 1997-06-20 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan |
Publications (3)
Publication Number | Publication Date |
---|---|
NO990088D0 true NO990088D0 (no) | 1999-01-08 |
NO990088L NO990088L (no) | 1999-03-10 |
NO326052B1 NO326052B1 (no) | 2008-09-08 |
Family
ID=11069065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19990088A NO326052B1 (no) | 1996-07-11 | 1999-01-08 | Anvendelse av S-(-)-N-propargyl-1-aminoindamin eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament (a) for behandling av neurotrauma eller (b) for forbedring av hukommelsen hos en post-CHI-pasient. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6277886B1 (no) |
EP (1) | EP0929298B1 (no) |
JP (1) | JP4368421B2 (no) |
CN (1) | CN1149985C (no) |
AT (1) | ATE328590T1 (no) |
AU (1) | AU3188097A (no) |
CA (1) | CA2260037C (no) |
DE (1) | DE69736066T2 (no) |
HU (1) | HU226961B1 (no) |
IL (1) | IL118836A (no) |
NO (1) | NO326052B1 (no) |
WO (1) | WO1998002152A1 (no) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
EP1372664A1 (en) | 2001-03-01 | 2004-01-02 | Hollis-Eden Pharmaceuticals Inc. | Use of certain steroids for treatment of blood cell deficiencies |
CA2496867A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
WO2004041151A2 (en) * | 2002-11-07 | 2004-05-21 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
AU2003290838A1 (en) | 2002-11-15 | 2004-06-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US8097608B2 (en) * | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
CA2547053C (en) | 2003-11-25 | 2014-05-27 | Technion Research & Development Foundation Ltd. | Compositions and methods for treatment of cardiovascular disorders and diseases |
JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
CA2574925A1 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
EP2471536A1 (en) | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
US20080261894A1 (en) * | 2005-02-17 | 2008-10-23 | Rivka Kreitman | Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis |
BRPI0608209A2 (pt) | 2005-02-23 | 2010-11-09 | Teva Pharma | mistura de partìculas, composição sólida, método para tratamento de um paciente com mal de parkinson, processo para preparação de uma composição, e, composição farmacêutica sólida |
US8263655B2 (en) * | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
JP2009521402A (ja) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
EP1956904B1 (en) * | 2005-12-09 | 2017-04-12 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Low-dose ladostigil for the treatment of mild cognitive impairment |
WO2007098264A2 (en) | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
CA2646250A1 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
PT2101569E (pt) * | 2006-12-14 | 2012-01-13 | Teva Pharma | Base de rasagilina sólida cristalina |
NZ577623A (en) * | 2006-12-14 | 2011-05-27 | Teva Pharma | Tannate salt of rasagiline |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
AU2008296908B2 (en) * | 2007-09-05 | 2014-01-09 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
BRPI0905680A2 (pt) * | 2008-01-11 | 2015-07-07 | Teva Pharma | "composição farmacêutica de uma composição farmacêutica" |
WO2009122351A2 (en) * | 2008-04-01 | 2009-10-08 | Kangwon National University | Anti-parkinsonian compounds mppe |
JP2011524353A (ja) * | 2008-06-10 | 2011-09-01 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリン軟ゼラチンカプセル |
US20090312436A1 (en) * | 2008-06-13 | 2009-12-17 | Ruth Levy | Rasagiline for parkinson's disease modification |
NZ589547A (en) | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
EP2299993A4 (en) * | 2008-06-19 | 2014-08-20 | Teva Pharma | PROCESS FOR PURIFYING THE BASE OF RASAGILINE |
US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
WO2011003938A1 (en) | 2009-07-09 | 2011-01-13 | Ratiopharm Gmbh | Salts of rasagiline and pharmaceutical preparations thereof |
JP6045347B2 (ja) | 2010-02-03 | 2016-12-14 | ファーマ ツー ビー リミテッド | ラサギリンの持続放出性製剤およびその使用 |
US8569379B2 (en) | 2010-07-27 | 2013-10-29 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
JP2014534196A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−ホルミル−プロパルギル−アミノインダン |
JP2014534197A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−メチル−プロパルギルアミノインダン |
CA2882072A1 (en) | 2012-08-17 | 2014-02-20 | Teva Pharmaceutical Industries Ltd. | Parenteral formulations of rasagiline |
CN104177610A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
CN104177611A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
CN111333517A (zh) * | 2018-12-19 | 2020-06-26 | 上海奥博生物医药技术有限公司 | 一种制备雷沙吉兰的改进方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
JP4782252B2 (ja) * | 1994-01-10 | 2011-09-28 | テバ ファーマシューティカル インダストリーズ リミテッド | 1−アミノインダン及びこれらの組成物 |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
-
1996
- 1996-07-11 IL IL11883696A patent/IL118836A/xx not_active IP Right Cessation
-
1997
- 1997-06-20 DE DE69736066T patent/DE69736066T2/de not_active Expired - Lifetime
- 1997-06-20 CA CA002260037A patent/CA2260037C/en not_active Expired - Lifetime
- 1997-06-20 JP JP50580698A patent/JP4368421B2/ja not_active Expired - Lifetime
- 1997-06-20 AU AU31880/97A patent/AU3188097A/en not_active Abandoned
- 1997-06-20 CN CNB971971994A patent/CN1149985C/zh not_active Expired - Lifetime
- 1997-06-20 AT AT97927353T patent/ATE328590T1/de not_active IP Right Cessation
- 1997-06-20 EP EP97927353A patent/EP0929298B1/en not_active Expired - Lifetime
- 1997-06-20 HU HU9904525A patent/HU226961B1/hu unknown
- 1997-06-20 WO PCT/IL1997/000205 patent/WO1998002152A1/en active IP Right Grant
-
1999
- 1999-01-08 NO NO19990088A patent/NO326052B1/no not_active IP Right Cessation
- 1999-01-11 US US09/228,153 patent/US6277886B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
HUP9904525A2 (hu) | 2000-11-28 |
JP2000514453A (ja) | 2000-10-31 |
EP0929298A1 (en) | 1999-07-21 |
IL118836A (en) | 2001-01-11 |
NO326052B1 (no) | 2008-09-08 |
AU3188097A (en) | 1998-02-09 |
CN1149985C (zh) | 2004-05-19 |
JP4368421B2 (ja) | 2009-11-18 |
CA2260037A1 (en) | 1998-01-22 |
ATE328590T1 (de) | 2006-06-15 |
NO990088L (no) | 1999-03-10 |
WO1998002152A1 (en) | 1998-01-22 |
EP0929298B1 (en) | 2006-06-07 |
CA2260037C (en) | 2007-01-23 |
DE69736066T2 (de) | 2006-12-28 |
CN1227486A (zh) | 1999-09-01 |
HU226961B1 (en) | 2010-03-29 |
US6277886B1 (en) | 2001-08-21 |
HUP9904525A3 (en) | 2000-12-28 |
DE69736066D1 (de) | 2006-07-20 |
IL118836A0 (en) | 1996-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO990088D0 (no) | Farmas÷ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindamin | |
HU913447D0 (en) | Medical preparations and their use in treating neurologic disorders | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
GB2254784B (en) | Film-coated solid dosage form of anti-migraine drug | |
UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
CA2114251A1 (en) | Igf-1 to improve the neural condition | |
CZ176595A3 (en) | The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes | |
CA2148194A1 (en) | Cyclopeptides of the formula i | |
CA2122058A1 (en) | Tgf-beta to improve neural outcome | |
CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
YU49215B (sh) | Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja | |
ATE202709T1 (de) | Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten | |
CA2374997A1 (en) | Il6ril6 chimera for the treatment of neurodegenerative diseases | |
IL164317A0 (en) | Statin therapy for enhancing cognitive maintenance | |
MXPA01009384A (es) | Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina. | |
CA2135752A1 (en) | Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease | |
NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
CA2097878A1 (en) | Therapeutic agent for neutropenia | |
NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
GB9209599D0 (en) | Novel therapy for the treatment of parkinsons disease | |
CA2154485A1 (en) | Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders | |
EP0621789A4 (en) | Pharmaceutical pentapeptide compositions and methods of use thereof. | |
IT1264428B1 (it) | Composizioni farmaceutiche per il trattamento della psoriasi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |